GSK Limits Its 340B Drug Discount Program
GlaxoSmithKline (GSK) has become the 14th drugmaker to limit its involvement in the 340B Drug Discount Program.
Designed to serve low-income patient populations in the U.S., the program in recent years has led to protracted fights between drugmakers and the government as drug companies complain that the use of contract pharmacies by hospitals and clinics leads to double billings and ineligible rebates.
Effective April 1, 2022, GSK will ship certain products purchased at the 340B price only to locations registered as a 340B covered entity or to a single contract pharmacy designated by the covered entity, but not to multiple contract pharmacies.
The Department of Health and Human Services (HSS) recently appealed court rulings that called into question the agency fining drugmakers who refuse to fully participate in the program.
GlaxoSmithKline PLC is a global healthcare company. The Company researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency virus (HIV), immuno-inflammation and oncology. Its Vaccines business has a portfolio of vaccines to help protect people from a range of diseases throughout their lives. Its vaccines tackle diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Its Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands that consumers trust, and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.
February 16, 2022
